UK MHRA accepts Ultragenyx gene therapy application for review
RARE•The UK MHRA accepted Ultragenyx’s marketing application for UX111 gene therapy for Sanfilippo syndrome Type A for review on Oct. 28, 2026. NICE’s evaluation will align with the regulatory review, targeting an NHS funding decision close to potential approval.
1. Application accepted for review
The UK MHRA accepted Ultragenyx’s marketing application for UX111 gene therapy for Sanfilippo syndrome Type A for review on Oct. 28, 2026. NICE’s evaluation will align with the regulatory review, targeting an NHS funding decision close to potential approval.
